Inve India ▾

Dishman Carbogen Amcis share price & results

Dishman Carbogen Amcis Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

CDMO manufacturing APIs, HiPo/ADC compounds and its own Vitamin D analogues across India, Europe and China.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue57.0 ₹ crore−9.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin-21.0 %−26.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-24.0 ₹ crore−900.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity0.29 %+1.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin7.64 %+1.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)0.24 %+4.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 6 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

Dishman Carbogen Amcis Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (0 achieved, 6 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA Margin (Group Level) for FY2620% for FY26
Call transcript, Q3 FY25 · 13 Feb 2025		Q3 FY25Q1 FY27:The target for FY26 was missed. No new information.
Call transcript, Q1 FY27 · 21 Aug 2026		Missed
Annual Net Debt Reduction₹100-200 crores every year
Call transcript, Q4 FY25 · 22 May 2025		Q4 FY25Q1 FY27:Net debt increased from CHF 146.8M to CHF 153.6M during the quarter, reversing the reduction trend and putting the renewed annual target of CHF 10-15M reduction at risk.
Call transcript, Q1 FY27 · 21 Aug 2026		At Risk
French Subsidiary ProfitabilityBreakeven in FY26
Call transcript, Q3 FY25 · 13 Feb 2025		Q3 FY25Q1 FY27:Management anticipates double-digit growth in the French entity in FY28-29 and noted the subsidiary is gaining market recognition, supporting the delayed FY28 breakeven target.
Call transcript, Q1 FY27 · 21 Aug 2026		On Track

Source: Inve Guidance Tracker for Dishman Carbogen Amcis Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Dishman Carbogen Amcis Limited's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹147.7 +6.38% · +₹8.86

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −48.0% 1Y

₹150₹200₹250₹300Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 4 Nov 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 21 Aug 2026

1Y: ₹283.9 on 24 Oct 2025 → ₹147.7. High ₹297.6 (4 Nov 2025), low ₹129.97 (30 Mar 2026).

Previous close
₹138.84
Market cap
₹2.2k Cr
52-week range
₹129.97 – ₹297.6
One year
−49.65%
Price to earnings (TTM to Jun 2026)
120.94×
Return on equity (TTM to Jun 2026)
0.29%

Overview

Symbol
NSE:DCAL
Exchange
NSE
Currency
INR

What Dishman Carbogen Amcis Limited does

Based on the company's own presentations, annual report and earnings calls.

Dishman Carbogen Amcis is a fully integrated Contract Development and Manufacturing Organisation (CDMO) that takes drug molecules from process R&D through late-stage clinical and commercial-scale manufacturing of APIs, high-potent APIs (HiPo) and antibody-drug-conjugate (ADC) drug-linkers/bulk-drug-substance/drug-product for global innovator pharmaceutical companies. It also sells its own portfolio of niche marketable molecules, chiefly Vitamin D analogues, cholesterol derived from sheep wool, and lanolin-related products, directly to formulators. The group runs development and manufacturing sites across India, Switzerland, UK, France, the Netherlands and China, with facilities cleared by regulators including USFDA, Swiss Medic, WHO, PMDA and NMPA.

Segments

  • CDMO
  • Marketable Molecules
Manufacturing facilities
23 multi-purpose manufacturing facilities globally
Countries with development & manufacturing sites
6 (India, Switzerland, UK, France, Netherlands, China)
Global clients served
250+
Total team strength (employees)
2,200+
R&D team strength
950+ dedicated scientists/staff across 32 R&D labs (incl. HiPo labs)
Total commercialised molecules
29
Founded 1983Headquarters Ahmedabad, IndiaEmployees 2,200 (FY26) Company website

How the price took the results

close before → close after

Q1 FY27
+0.7%
21 Aug
Q4 FY26
+12.2%
20 May
Q3 FY26
−7.8%
4 Feb
Q2 FY26
−10.0%
5 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Dishman Carbogen Amcis Limited

Free account: one company. Everything above stays public.

Write why you follow Dishman Carbogen Amcis Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Dishman Carbogen Amcis Limited

Guides on how to read this kind of business and the numbers that matter.